These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31511565)

  • 1. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
    Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
    Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
    Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
    Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
    Cai S; Chen Z; Wang Y; Wang M; Wu J; Tong Y; Chen L; Lu C; Yang H
    Theranostics; 2021; 11(4):1970-1981. PubMed ID: 33408792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
    Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
    Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
    Wei T; Li M; Zhu Z; Xiong H; Shen H; Zhang H; Du Q; Li Q
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):691-701. PubMed ID: 33389078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.
    Kumar D; Mishra A; Lisok A; Kureshi R; Shelake S; Plyku D; Sen R; Doucet M; De Silva RA; Mease RC; Forde PM; Jaffee EM; Desai P; Ganguly S; Gabrielson E; Vaidya D; Spangler JB; Nimmagadda S
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34508005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
    Kong T; Ahn R; Yang K; Zhu X; Fu Z; Morin G; Bramley R; Cliffe NC; Xue Y; Kuasne H; Li Q; Jung S; Gonzalez AV; Camilleri-Broet S; Guiot MC; Park M; Ursini-Siegel J; Huang S
    Cancer Res; 2020 Feb; 80(3):444-457. PubMed ID: 31722999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
    Lu F; Zhao Y; Pang Y; Ji M; Sun Y; Wang H; Zou J; Wang Y; Li G; Sun T; Li J; Ma D; Ye J; Ji C
    Cancer Lett; 2021 Jan; 497():178-189. PubMed ID: 33091534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
    Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
    Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
    Wang X; Yang X; Zhang C; Wang Y; Cheng T; Duan L; Tong Z; Tan S; Zhang H; Saw PE; Gu Y; Wang J; Zhang Y; Shang L; Liu Y; Jiang S; Yan B; Li R; Yang Y; Yu J; Chen Y; Gao GF; Ye Q; Gao S
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6640-6650. PubMed ID: 32161124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
    Coombs MRP; Harrison ME; Hoskin DW
    Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.